Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation
April 16, 2024 08:00 ET
|
Provectus Biopharmaceuticals Inc.
Names Ed Pershing as Chief Executive Officer and Dominic Rodrigues as President KNOXVILLE, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the...
EveLab Insight Furthers Its Reach into the European Market at Cosmoprof Bologna
April 10, 2024 09:30 ET
|
EveLab Insight
EveLab Insight built further inroads into the European market at Cosmoprof Bologna.
Olansky Dermatology & Aesthetics welcomes physician assistant, expands hours
April 09, 2024 15:56 ET
|
Olansky Dermatology & Aesthetics
Olansky Dermatology & Aesthetics welcomes physician assistant and expands hours at Buckhead location.
[Latest] Global Beauty Supplement Market Size/Share Worth USD 8.2 Billion by 2033 at a 12.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
April 01, 2024 11:30 ET
|
Custom Market Insights
Austin, TX, USA, April 01, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Beauty Supplement Market Size, Trends and Insights By Form (Tablets, Capsules,...
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
April 01, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2023 Earnings
March 27, 2024 16:01 ET
|
STRATA Skin Sciences, Inc.
HORSHAM, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or “the Company”), a medical technology company dedicated to developing, commercializing and...
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
March 21, 2024 16:01 ET
|
Journey Medical Corporation
Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 Achieved $15.6 million in operating cost...
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
March 18, 2024 08:30 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., March 18, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily...
Acute Bacterial Skin and Skin Structure Infections Market Projections Reveal Dynamic Growth in Asia Pacific Region Amid Global Rise to USD 2.31 Billion by 2034
March 18, 2024 05:11 ET
|
Research and Markets
Dublin, March 18, 2024 (GLOBE NEWSWIRE) -- The "Global Acute Bacterial Skin and Skin Structure Infections Market by Type of Infection, Route of Administration, Distribution Channel, and By Region"...
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
March 15, 2024 08:30 ET
|
Journey Medical Corporation
SCOTTSDALE, Ariz., March 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the...